Company Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Fate Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
3.8 ^USD	-1.81%		-20.67%	+1.60%

04-22	Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	CI
03-21	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Number of employees: 181

USD in Million	2022	Weight	2023	Weight	Delta
Cellular Immunotherapies 100.0 %	96	100.0 %	64	100.0 %	-34.03%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	96	100.0 %	64	100.0 %	-34.03%

Managers	Title	Age	Since
J. Wolchko FOU	Founder	53	26/04/07
Edward Dulac DFI	Director of Finance/CFO	49	16/08/20
William Rastetter CHM	Chairman	75	31/10/11
Wen Bo Wang CTO	Chief Tech/Sci/R&D Officer	-	07/10/18
Bahram Valamehr CTO	Chief Tech/Sci/R&D Officer	47	31/07/18
Jerome C. Bressi LAW	General Counsel	-	30/11/18
Cindy Tahl LAW	General Counsel	51	31/12/08
Jim Beitel PRN	Corporate Officer/Principal	-	13/09/17

Members of the board	Title	Age	Since
Robert Epstein BRD	Director/Board Member	69	16/03/14
Robert Hershberg BRD	Director/Board Member	61	30/04/20
Tim Coughlin BRD	Director/Board Member	57	31/07/13
William Rastetter CHM	Chairman	75	31/10/11
John Mendlein FOU	Founder	64	26/04/07
J. Wolchko FOU	Founder	53	26/04/07
Michael Lee BRD	Director/Board Member	45	30/07/18
Karin Jooss BRD	Director/Board Member	59	13/03/19
Shefali Agarwal BRD	Director/Board Member	50	14/07/19
Yuan Xu BRD	Director/Board Member	56	02/08/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	113,172,530	111,508,920 ( 98.53 %)	0	98.53 %
Stock B	0	2,761,108	0	0

Name	Equities	%	Valuation
Redmile Group LLC 13.28 %	13,180,388	13.28 %	97 M $
Redmile Group LLC 13.27 %	13,169,057	13.27 %	97 M $
ARK Investment Management LLC 10.39 %	10,312,167	10.39 %	76 M $
BlackRock Advisors LLC 10.33 %	10,246,793	10.33 %	75 M $
Vanguard Fiduciary Trust Co. 9.365 %	9,293,363	9.365 %	68 M $
Boxer Capital LLC 6.511 %	6,461,000	6.511 %	47 M $
Point72 Asset Management LP 4.983 %	4,945,146	4.983 %	36 M $
Bellevue Asset Management AG 4.889 %	4,851,579	4.889 %	36 M $
D.E. Shaw & Co., Inc. 3.610 %	3,581,979	3.610 %	26 M $
Point72 Asset Management LP 3.516 %	3,489,163	3.516 %	26 M $

Name	Equities	%	Valuation
Redmile Group LLC 97.93 %	2,761,108	97.93 %	20 M $

Fate Therapeutics, Inc.

12278 Scripps Summit Drive

92131, San Diego

+858 875 1800

http://www.fatetherapeutics.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.8 USD

Average target price

7.8 USD

Spread / Average Target

+105.26%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FATE THERAPEUTICS, INC.	+1.60%	433M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs